A Phase 1 interventional study of Gemcitabine, local delivery in Pancreatic Cancer, sponsored by RenovoRx. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-07.
Sponsored by RenovoRx · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies testing gemcitabine in Pancreatic Neoplasms — 29 open to participants now, 44 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 247th largest by enrollment of the 352 interventional ones that give a count, is one of 20 that started in 2015, is one of 87 in phase 1, and was the 259th registered.
3,897 studies on the registry are indexed under Pancreatic Neoplasms; 1,003 are open to participants now.
Browse Pancreatic Neoplasms studies →29 of the 369 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Revolution Medicines, Inc. · Sites in United States
Ages 18+
Smartwise Sweden AB · Sites in Sweden
Ages 18+
Revolution Medicines, Inc. · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
Shanghai Hengrui Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Dartmouth-Hitchcock Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 743 Pancreatic Neoplasms studies recruiting now, 477 (64%) set no upper age limit and 151 (20%) stop at 75 or younger; 40 take children under 18; 59 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 125 · Phase 2 238 · Phase 3 36 · Phase 4 2
First in 1995; this study’s year is marked. 20 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 352 interventional studies. Of the 268 that completed or were terminated, 80 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 369 have an industry lead sponsor. The 10 most frequent:
RenovoRx is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
RenovoRx has 3 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
15 of the studies testing gemcitabine in Pancreatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06953999Phase 3AkesoA Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer | 2027-05-14 |
| NCT02340117SynerGene Therapeutics, Inc.Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | 2026-12 |
| NCT03652428University of Maryland, BaltimorePhase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC) | 2026-12-31 |
| NCT04115163Anne NoonanBiologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer | 2026-12-31 |
| NCT04894643EBG MedAustron GmbHPreoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 369 studies testing gemcitabine in Pancreatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
Patients diagnosed with unresectable pancreatic cancer who may or may not have had prior chemotherapy or radiation therapy may be eligible to enroll in this dose escalation study to determine the maximum tolerated dose of gemcitabine to be delivered locally to the pancreatic tumors using the RenovoCath R120 catheter. Patients enrolled may receive up to 8 catheterizations for delivering gemcitabine directly to the pancreatic tumors starting at a reduced dose( 1/4 of standard i.v. gemcitabine dose), then every two doses, increase the dose by 25% if there are no toxicities up to a maximum dose of 1000 mg/m2. There are four cycles, with two doses per cycle. Imaging studies will be conducted as well as assessment for standard, myelosuppresive and gastric toxicities will be assessed. Pain will also be measured throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be eligible to participate in the study if all of the following criteria are met:
Adequate renal, and bone marrow function described as:
Adequate Hepatic function (endoscopic or percutaneous drainage as needed) described as:
Exclusion Criteria:
Subjects will be excluded from participation in the study if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gemcitabine; 1 cycle, two doses per cycle; 250mg/m2 dose
Drug: Gemcitabine, local delivery
Gemcitabine; 1 cycle, two doses per cycle; 500mg/m2 dose
Drug: Gemcitabine, local delivery
Gemcitabine; 1 cycle, two doses per cycle; 750mg/m2 dose
Drug: Gemcitabine, local delivery
Gemcitabine; 1 cycle, two doses per cycle; 1000mg/m2 dose
Drug: Gemcitabine, local delivery
Intra-arterial targeted drug delivery
Also known as: Gemzar
Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas
Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.
Time frame: 1 week post treatment
CA19-9 Tumor Reduction
Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.
Time frame: 1 week after treatment
| Milestone | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| Started | 20 | 0 | 0 | 0 |
| Completed | 16 | 0 | 0 | 0 |
| Not completed | 4 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 |
| Milestone | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| Started | 0 | 15 | 0 | 0 |
| Completed | 0 | 15 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| Started | 0 | 0 | 11 | 0 |
| Completed | 0 | 0 | 11 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 8 |
| Completed | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Maximum Tolerated Dose (MTD) of gemcitabine administered intra-arterially to the pancreatic tumor(s) using the RenovoCath™ RC120 catheter. One week post treatment, toxicities will be assessed to determine if there is a pre-defined Dose Limiting Toxicity necessitating dose stopping or holding.
| mg/m^2 | Gemcitabine, Local Delivery |
|---|---|
| Determine the Maximum Tolerated Dose of Gemcitabine to be Delivered Locally to the Pancreas | 1000 |
Measurements of CA19-9 tumor marker are measured pre-treatment and at various time points (starting with one week) post treatment.
Results for this outcome have not been posted.
Collected over Adverse events were collected during the treatment period, an average of 2.5 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gemcitabine, Local Delivery (Dose 1) | 0/20 (0%) | 5/20 (25%) | 7/20 (35%) |
| Gemcitabine, Local Delivery (Dose 2) | 0/15 (0%) | 4/15 (26.7%) | 7/15 (46.7%) |
| Gemcitabine, Local Delivery (Dose 3) | 0/11 (0%) | 3/11 (27.3%) | 4/11 (36.4%) |
| Gemcitabine, Local Delivery (Dose 4) | 0/8 (0%) | 2/8 (25%) | 0/8 (0%) |
| Event | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| Pain - Abdominal (NOS)Gastrointestinal disorders | 0/20 | 0/15 | 0/11 | 1/8 |
| SepsisBlood and lymphatic system disorders | 2/20 | 0/15 | 0/11 | 1/8 |
| Intraoperative Arterial Injury / DissectionInjury, poisoning and procedural complications | 1/20 | 1/15 | 1/11 | 0/8 |
| Intraoperative Arterial Injury - Lower ExtremityInjury, poisoning and procedural complications | 0/20 | 0/15 | 1/11 | 0/8 |
| Respiratory FailureRespiratory, thoracic and mediastinal disorders | 0/20 | 0/15 | 1/11 | 0/8 |
| DehydrationMetabolism and nutrition disorders | 0/20 | 1/15 | 0/11 | 0/8 |
| Duodenal ObstructionInjury, poisoning and procedural complications | 0/20 | 1/15 | 0/11 | 0/8 |
| GastritisGastrointestinal disorders | 0/20 | 1/15 | 0/11 | 0/8 |
| Cardiac arrestCardiac disorders | 1/20 | 0/15 | 0/11 | 0/8 |
| InfectionInfections and infestations | 1/20 | 0/15 | 0/11 | 0/8 |
| Event | Gemcitabine, Local Delivery (Dose 1) | Gemcitabine, Local Delivery (Dose 2) | Gemcitabine, Local Delivery (Dose 3) | Gemcitabine, Local Delivery (Dose 4) |
|---|---|---|---|---|
| FatigueGeneral disorders | 1/20 | 2/15 | 1/11 | 0/8 |
| VomitingGastrointestinal disorders | 0/20 | 2/15 | 1/11 | 0/8 |
| FeverGeneral disorders | 0/20 | 1/15 | 1/11 | 0/8 |
| Median arcuate ligament syndromeMusculoskeletal and connective tissue disorders | 0/20 | 0/15 | 1/11 | 0/8 |
| NauseaEar and labyrinth disorders | 1/20 | 1/15 | 0/11 | 0/8 |
| Vasovagal episodeVascular disorders | 0/20 | 1/15 | 0/11 | 0/8 |
| Arterial spasmVascular disorders | 1/20 | 0/15 | 0/11 | 0/8 |
| ChillsGeneral disorders | 1/20 | 0/15 | 0/11 | 0/8 |
| IncontinenceGastrointestinal disorders | 1/20 | 0/15 | 0/11 | 0/8 |
| Intraoperative arterial injury - lower extremityInjury, poisoning and procedural complications | 1/20 | 0/15 | 0/11 | 0/8 |
| Age, Categorical(Participants) | Gemcitabine, Local Delivery |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 9 |
| >=65 years | 11 |
| Age, Continuous(years) | Gemcitabine, Local Delivery |
|---|---|
| Median | 67.5 ± 9.72 |
| Sex: Female, Male(Participants) | Gemcitabine, Local Delivery |
|---|---|
| Female | 11 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | Gemcitabine, Local Delivery |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 18 |
| Unknown or Not Reported | 1 |
| Race (NIH/OMB)(Participants) | Gemcitabine, Local Delivery |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 17 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Gemcitabine, Local Delivery |
|---|---|
| United States | 20 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2015, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2021, 4 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gemcitabine
RenovoRx